Aucta’s R&D engine is built on end-to-end internal innovation and a dual-site infrastructure across Shanghai and New Jersey. Its scientific foundation rests on three proprietary technology platforms:

• AucPed^TM      (pediatric formulations),

• AucTrol^TM     (controlled-release oral technologies), and

• AucMist^TM     (nasal drug delivery).

These platforms enable the creation of differentiated dosage forms such as oral suspensions, extended-release capsules, and intranasal sprays, exemplified by its flagship product Motpoly XR^TM, the world’s first once-daily lacosamide.